Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16235771 | 0.82 | KDM4E (0.46) | KDM4EPOLBPDE4DL3MBTL1KMT2A | |
| SCHEMBL719025 | 0.81 | KDM4E (0.49) | KDM4EPOLBPDE4DL3MBTL1KMT2A | |
| SCHEMBL946588 | 0.80 | KDM4E (0.47) | KDM4EPOLBPDE4DL3MBTL1KMT2A | |
| SCHEMBL3376695 | 0.80 | KDM4E (0.51) | KDM4EPOLBPDE4DL3MBTL1KMT2A | |
| SCHEMBL19780563 | 0.79 | NPSR1 (0.46) | KDM4EL3MBTL1KMT2ACYP1A2MAPT | |
| SCHEMBL953967 | 0.79 | KDM4E (0.46) | KDM4EPOLBPDE4DL3MBTL1KMT2A | |
| SCHEMBL983844 | 0.79 | L3MBTL1 (0.48) | KDM4EPOLBPDE4DL3MBTL1KMT2A | |
| SCHEMBL1431096 | 0.79 | KDM4E (0.46) | KDM4EPOLBPDE4DL3MBTL1KMT2A | |
| SCHEMBL31728192 | 0.77 | POLB (0.48) | KDM4EPOLBPDE4DL3MBTL1KMT2A | |
| SCHEMBL16559320 | 0.77 | POLB (0.48) | KDM4EPOLBPDE4DL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391690-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | LIGACHEM BIOSCIENCES INC. (KR) | 2025-08-19 | — | — | US | disclosed |
| EP-3472171-B1 | SUBSTITUTED TRICYCLIC HERTEOCYCLIC COMPOUNDS AND USE THEREOF | SUZHOU YABAO PHARMACEUTICAL R&D CO LTD (CN) | 2025-04-23 | — | — | EP | disclosed |
| US-12084437-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2024-09-10 | — | — | US | disclosed |
| CN-118580241-A | Tetrahydropyrrolo [3,4-c ] pyrazole compound, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| CN-114466849-B | N-substituted-3, 4- (fused 5-ring) -5-phenyl-pyrrolidin-2-one compounds as ISOQC and/or inhibitors of QC enzymes | 欣尼克免疫有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-117915918-A | Soluble adenylate cyclase (sAC) inhibitors and uses thereof | 康奈尔大学 | 2024-04-19 | — | — | CN | disclosed |
| EP-4329762-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | Cornell University (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| US-20140349990-A1 | Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| US-20140349990-A1 | Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| US-20140349990-A1 | Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| US-8841456-B2 | 1,5-naphthyridine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-09-23 | — | — | US | disclosed |
| US-8841456-B2 | 1,5-naphthyridine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-09-23 | — | — | US | disclosed |
| US-20130210807-A1 | Tricyclic Compounds as Allosteric Modulators of Metabotropic Glutamate Receptors. | MERCK SHARP & DOHME CORP. | 2013-08-15 | — | — | US | disclosed |
| US-20130210807-A1 | Tricyclic Compounds as Allosteric Modulators of Metabotropic Glutamate Receptors. | MERCK SHARP & DOHME CORP. | 2013-08-15 | — | — | US | disclosed |
| WO-2012006760-A1 | TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012008999-A2 | TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-1996040704-A1 | PYRAZOLE-RELATED DERIVATIVES ENDOWED WITH ANTITUMOR AND ANTIVIRAL ACTIVITIES, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL FORMULATIONS CONTAINING THEM | SARDINIAN ANTIVIRAL RESEARCH CONSORTIUM SARC S.C.R.L. (IT) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210807-A1 | Tricyclic Compounds as Allosteric Modulators of Metabotropic Glutamate Receptors. | GRM3, GRM6, GRM1 | KDM4E 1020/4885POLB 4468/4885PDE4D 2561/4885 |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | KDM4E 4664/4885POLB 3155/4885PDE4D 50/4885 |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | KDM4E 2150/4885POLB 1606/4885PDE4D 2162/4885 |
| US-12391690-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | ENPP2, PLA2G10, LPCAT1 | KDM4E 3095/4885POLB 4646/4885PDE4D 757/4885 |
| US-20140349990-A1 | Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease | PKD1, PKD2, REN | KDM4E 2965/4885POLB 2315/4885PDE4D 114/4885 |
| US-12084437-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | KDM4E 2475/4885POLB 4577/4885PDE4D 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.